Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN)

• Status: Completed
• Trial end date: 2006-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the TCRN is to accelerate research in the management of thalassemia, standardize existing treatments, and evaluate new ones in a network of clinical centers in North America. The emphasis will be on clinical trials that help identify optimal therapy. Therapeutic trials may involve investigational drugs, drugs already approved but not currently used, and drugs currently used.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: HealthCore-NERI; New England Research Institutes
• Collaborators: National Heart, Lung, and Blood Institute (NHLBI); Thalassemia Clinical Research Network
• Treatments: Decitabine; Deferiprone; Deferoxamine; Sildenafil Citrate

Criteria

Please refer to specific studies for eligibility criteria.